{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:32:40Z","timestamp":1775676760777,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T00:00:00Z","timestamp":1646611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19kk0205016"],"award-info":[{"award-number":["JP19kk0205016"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pseudomyxoma peritonei is a rare disease condition mainly caused by primary mucinous tumors from the appendix and rarely from the ovary, such as when mucinous ovarian tumors arise from within a teratoma. Molecular analyses of pseudomyxoma from the appendix showed that <jats:italic>KRAS<\/jats:italic> and <jats:italic>GNAS<\/jats:italic> pathogenic variants are common genetic features of pseudomyxoma peritonei. However, the origin of the tumors is difficult to be identified via genetic variants alone. This study presents a case of pseudomyxoma peritonei of ovarian origin, which was diagnosed by comprehensive genomic profiling with ploidy analysis in a series of primary, recurrent, and autopsy tumor specimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 40-year-old woman was diagnosed with Stage IC2 mucinous ovarian tumor of borderline malignancy with mature cystic teratoma, upon clinical pathology. Immunohistochemical analysis suggested that the mucinous tumor was derived from the intestinal component of an ovarian teratoma. Three years later, intraperitoneal recurrence was detected, which subsequently progressed to pseudomyxoma peritonei. Genomic analysis detected <jats:italic>KRAS<\/jats:italic> (G12D), <jats:italic>GNAS<\/jats:italic> (R201C), and <jats:italic>FBXW7<\/jats:italic> (R367*) variants in the primary tumor. In addition, the tumor showed aneuploidy with loss of heterozygosity (LOH) in all its chromosomes, which suggested that the primary ovarian tumor was derived from germ cells. Existence of one Barr body suggested the existence of uniparental disomy of the tumors throughout the genome, instead of a haploid genotype. All three pathogenic variants remained positive in the initial recurrent tumor, as well as in the paired DNA from the whole blood in pseudomyxoma peritonei. The pathogenic variant of <jats:italic>KRAS<\/jats:italic> (G12D) was also identified in the autopsy specimen of the appendix by droplet digital polymerase chain reaction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study pathologically and genetically confirmed that the primary ovarian borderline tumor was derived from the intestinal component of an ovarian teratoma, and that the subsequent pseudomyxoma peritonei progressed from the primary ovarian tumor. Integrative genomic analysis was useful to identify cellular origin of tumors, as well as to precisely interpret the process of disease progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12920-022-01188-x","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:06:57Z","timestamp":1646647617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Ayumi","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Rokutan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2468-9573","authenticated-orcid":false,"given":"Katsutoshi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuyo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tatsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shinozaki-Ushiku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Mano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Aburatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,7]]},"reference":[{"key":"1188_CR1","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/cas.13968","volume":"110","author":"S Kohsaka","year":"2019","unstructured":"Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, Oda Y, Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H. Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. Cancer Sci. 2019;110:1464\u201379.","journal-title":"Cancer Sci"},{"key":"1188_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1055-3207(03)00026-7","volume":"12","author":"BJ Moran","year":"2003","unstructured":"Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12:585\u2013603.","journal-title":"Surg Oncol Clin N Am"},{"key":"1188_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/00000478-199105000-00001","volume":"15","author":"RH Young","year":"1991","unstructured":"Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol. 1991;15:415\u201329.","journal-title":"Am J Surg Pathol"},{"key":"1188_CR4","first-page":"591","volume":"18","author":"RA Prayson","year":"1994","unstructured":"Prayson RA, Hart WR, Petras RE. Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol. 1994;18:591\u2013603.","journal-title":"Am J Surg Pathol"},{"key":"1188_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0046-8177(96)90370-6","volume":"27","author":"RF Chuaqui","year":"1996","unstructured":"Chuaqui RF, Zhuang Z, Emmert-Buck MR, Bryant BR, Nogales F, Tavassoli FA, Merino MJ. Genetic analysis of synchronous mucinous tumors of the ovary and appendix. Hum Pathol. 1996;27:165\u201371.","journal-title":"Hum Pathol"},{"issue":"12","key":"1188_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/cam4.542","volume":"4","author":"R Noguchi","year":"2015","unstructured":"Noguchi R, Yano H, Gohda Y, Suda R, Igari T, Ohta Y, Yamashita N, Yamaguchi K, Terakado Y, Ikenoue T, Furukawa Y. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med. 2015;4(12):1809\u201316.","journal-title":"Cancer Med"},{"key":"1188_CR7","doi-asserted-by":"publisher","first-page":"E282","DOI":"10.1002\/ijc.29245","volume":"136","author":"P Nummela","year":"2015","unstructured":"Nummela P, Saarinen L, Thiel A, J\u00e4rvinen P, Lehtonen R, Lepist\u00f6 A, J\u00e4rvinen H, Aaltonen LA, Hautaniemi S, Ristim\u00e4ki A. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. Int J Cancer. 2015;136:E282\u20139.","journal-title":"Int J Cancer"},{"key":"1188_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/163676a0","volume":"163","author":"ML Barr","year":"1949","unstructured":"Barr ML, Bertram EG. A morphological distinction between neurons of the male and female, and the behaviour of the nucleolar satellite during accelerated nucleoprotein synthesis. Nature. 1949;163:676.","journal-title":"Nature"},{"key":"1188_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/jcp.2004.025148","volume":"58","author":"N Pranesh","year":"2005","unstructured":"Pranesh N, Menasce LP, Wilson MS, O\u2019Dwyer ST. Pseudomyxoma peritonei: unusual origin from an ovarian mature cystic teratoma. J Clin Pathol. 2005;58:1115\u20137.","journal-title":"J Clin Pathol"},{"key":"1188_CR10","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.2147\/CMAR.S264474","volume":"12","author":"F Yan","year":"2020","unstructured":"Yan F, Shi F, Li X, Yu C, Lin Y, Li Y, Jin M. Clinicopathological characteristics of pseudomyxoma peritonei originated from ovaries. Cancer Manag Res. 2020;12:7569\u201378.","journal-title":"Cancer Manag Res"},{"key":"1188_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/gyno.1993.1044","volume":"48","author":"G Ueda","year":"1993","unstructured":"Ueda G, Fujita M, Ogawa H, Sawada M, Inoue M, Tanizawa O. Adenocarcinoma in a benign cystic teratoma of the ovary: report of a case with a long survival period. Gynecol Oncol. 1993;48:259\u201363.","journal-title":"Gynecol Oncol"},{"key":"1188_CR12","doi-asserted-by":"publisher","first-page":"ED11","DOI":"10.1111\/crj.12171","volume":"10","author":"S Roy","year":"2016","unstructured":"Roy S, Mukhopadhayay S, Gupta M, Chandramohan A. Mature cystic teratoma with co-existent mucinous cystadenocarcinoma in the same ovary\u2014a diagnostic dilemma. J Clin Diagn Res. 2016;10:ED11\u20133.","journal-title":"J Clin Diagn Res"},{"issue":"4","key":"1188_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/PGP.0000000000000258","volume":"35","author":"ME Clark","year":"2016","unstructured":"Clark ME, Will MD. Intestinal-type adenocarcinoma arising in a mature cystic teratoma of the ovary. Int J Gynecol Pathol. 2016;35(4):352\u20136.","journal-title":"Int J Gynecol Pathol"},{"key":"1188_CR14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O\u2019Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1188_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O\u2019Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-P\u00e9rez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402.","journal-title":"N Engl J Med"},{"key":"1188_CR16","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, Fujiwara K, Vergote I, Colombo N, M\u00e4enp\u00e4\u00e4 J, Selle F, Sehouli J, Lorusso D, Guerra Al\u00eda EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marm\u00e9 F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328.","journal-title":"N Engl J Med"},{"key":"1188_CR17","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355:eaaf8399.","journal-title":"Science"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-022-01188-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-022-01188-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T10:17:11Z","timestamp":1646648231000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-022-01188-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1188"],"URL":"https:\/\/doi.org\/10.1186\/s12920-022-01188-x","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,7]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the University of Tokyo (G10114-15).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written informed consent for publication of all clinical information from the patient. As well, written consent for publication of identifying images, other personal and clinical details was obtained from the next of kin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Oda received a research grant from Konica Minolta, INC. and AstraZenea plc., and lecture fees from Chugai Pharmaceutical Co., Ltd. and AstraZenea plc. Dr. Aburatani received grants from Sysmex Corporation and the Japan Agency for Medical Research and Development (AMED) during the study. Dr. Mano received grants from Sysmex Corporation during the study, and from Konica Minolta, outside the submitted work. In addition, Dr. Mano and Dr. Kohsaka have a patent IP for design and analytical methods related to Todai OncoPanel issued to the University of Tokyo. The sequencing analysis and interpretation of the data were performed under a grant from the Program for an Integrated Database of Clinical and Genomic Information (JP19kk0205016) from the Japan Agency for Medical Research and Development and a grant by Sysmex Corporation. The other authors have no conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}